Vantage logo

Fate runs out of excuses

The plug is pulled on a deal with J&J, and Fate swings the axe over its staff and NK cell pipeline.

Vantage logo

Cytokine players keep the faith

The demise of Nektar’s bempegaldesleukin has not stemmed the tidal wave of companies developing IL-2 and IL-15 therapies.